+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      IgA Nephropathy: Association of a History of Macroscopic Hematuria Episodes with Increased Production of Polymeric IgA

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          From the clinical point of view patients with IgA nephropathy present two main symptoms. Some patients have episodes of macroscopic hematuria, either isolated or recurrent, while others present only asymptomatic urinary abnormalities. Although these differences could be due to age-related, geographical or other unknown reasons, in this paper we studied whether patients with these two clinical manifestations differ in some IgA immunological aspects, described occasionally as abnormal in this disease. The following results were obtained: patients having a history of macroscopic hematuria episodes (n = 29) had a significant increase in the percentage of blood polymeric-IgA-producing cells (68 ± 12%) and in the T cells with IgA Fc-receptors (Tα cells; 14.5 ± 3%) in relation to those having only asymptomatic urinary abnormalities (n = 13; 48 ± 11 and 11.8 ± 3%, respectively). However, there was no difference in the two groups of patients in relation to the serum IgA levels, percentage of IgA-bearing cells, in vitro synthesis of IgA, T-cell subpopulation and generation of Con A-Ig A suppressor cells. Since these patients did not differ in the age of the apparent onset of the disease, in age at the moment of the study or in the activity of the disease determined by hematuria, our results afford an immunological support suggesting the existence of two subgroups of patients with IgA nephropathy.

          Related collections

          Author and article information

          S. Karger AG
          05 December 2008
          : 45
          : 2
          : 98-103
          Servicio de Nefrología, Fundación Jiménez Díaz, Madrid, Spain
          184087 Nephron 1987;45:98–103
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article